Annual Cardiologists Meeting

Cardiologist 2018

Theme: Recent Advances and Future Trends in Cardiology Research

The Annual Cardiologist Meeting will be held in Madrid, Spain during November 26-27, 2018 organized by Meetings International. This Cardiology Conference will lay a platform for scientists, world-class professors, and cardiologists to discuss an approach for various types of cardiovascular diseases, researches, medicines, and advanced technologies. This Conference is designed to provide diverse and current education that will keep medical professionals alongside the issues affecting the diagnosis, treatment of cardiac disorders and prevention. The vision behind this conference is to serve as a unique global platform for cardiologists, cardiac surgeons and researchers from world-renowned institutions to share and exchange new clinical studies and advancements in dealing with cardiac diseases. The conference theme Recent advances and future trends in Cardiology Research that focuses to share novel approaches related to cardiology and exploring the challenges concerning excellence in renal research and advancements. Meetings International (Meetings Int.) is a global leader in producing high-quality conferences, meetings, workshops and symposia in all major fields of medicine, science, and technology. Since its inception, Meetings Int. has been associated with national and international associations, corporations and high-level individuals, dedicated to hosting world-class conferences and events. Meetings Int. supports broad scope research and peer review at a broad range of specialists around the world.

Target Audience:

  • Cardiologists
  • Cardiac Surgeons
  • Cardiac Nurses
  • Professors, Lecturers from Medical Universities and Institutes
  • Directors, CEOs, Senior Managers, and Business Professionals
  • Cardiology Associations and Societies 
  • Students, Researchers
  • Medical devises Manufacturing Companies 
  • Cardiac Drug manufacturing Companies

Why Attend?

The Annual Cardiologist Meeting is among the World’s leading Cardiology Conferences. This Conference will conduct demonstrations, distribute information, meet with current famous & potential researchers and receive name recognition at this 2-day event.  Broadly acclaimed speakers, the most recent frameworks, methodologies, and the most current updates in Cardiology field are indications of this conference. Moreover, this conference will comprise of major sessions designed to offer comprehensive sessions that address current issues in the various field of Cardiovascular research. World-renowned speakers, the most recent techniques, tactics, and the newest updates in the Cardiology field will be hallmarks of this conference.

The benefits provided to the attendees are:

  • Certificates will be provided to all speakers, delegates, and students
  • Opportunity to meet world’s renowned at this event
  • Keynote forums by Prominent Physicians & Professors
  • Best platform for Global business and networking opportunities
  • Oral/Poster presentations by Young Researchers
  • Best poster award for students

Session 1: Preventive Cardiology and Lifestyle Medicine:

Multifactorial risk factor modification and control, especially interventions designed to reduce total cholesterol, systolic blood pressure, smoking prevalence, overweight/ obesity, diabetes mellitus, and physical inactivity, can have a profound and favorable impact on decreasing the incidence of initial and recurrent cardiovascular events. Between 1980 and 2000, mortality rates from coronary heart disease (CHD) fell by 40%. Using a previously validated statistical model (IMPACT), researchers attempted to determine how much of this decrease could be explained by the use of medical and surgical treatments as opposed to changes in risk factors among US adults aged 25 to 84 years. Approximately half of the decline in cardiovascular deaths was attributed to reductions in major risk factors (obesity and diabetes mellitus were notable exceptions), and approximately half was attributed to evidence-based medical therapies (eg, secondary prevention medications, rehabilitation, and initial treatments for acute myocardial infarction [AMI]).

Session 2: Cardiovascular Disease and Nutrition:

The major cardiovascular diseases affecting the developed world have at their core atherosclerosis and hypertension, both of which are profoundly affected by diet and can be approached, at least in part, from a nutritional point of view, as can the increasing “epidemic” of obesity. Diet is a multi-component mixture of many nutrients, which may interact with one another. The definitive study of nutrients and their impact on the cardiovascular disease can be a daunting enterprise. Many dietary risk factors contribute to these diseases in various environmental and ethnic settings. These risk factors are often in evidence in youth so that preventive measures must be initiated early in life. Although most of the information about nutritional risk factors and cardiovascular disease derives from studies in the developed world, the situation is rapidly evolving toward epidemic proportions in the developing world where a major burden on the economy and health services will be imposed.

Session 3: Echo Cardiography and Cardiac Imaging:

Cardiac imaging is a subspecialty of diagnostic radiology. A cardiac radiologist supervises or performs and then interprets medical images to diagnose diseases of the heart such as heart disease, leaky heart valves and defects in the size and shape of the heart. Its applications include assessment of myocardial ischemia and viability, cardiomyopathies, myocarditis, iron overload, vascular diseases, and congenital heart disease. It is the reference standard for the assessment of cardiac structure and function and is valuable for diagnosis and surgical planning in complex congenital heart disease. A cardiac radiologist uses imaging techniques such as X-rays, ultrasound (echocardiograms), CT (computed tomography) scans and MRI (magnetic resonance imaging) scans. These tests are used to screen for heart disease, determine what is causing your symptoms and monitor your heart and find out if your treatment is working. Cardiac (heart) imaging procedures include:

Session 4: Cardiac-Oncology:

The editorial mission of Cardiac-Oncology is to advance the science and practice of this emerging field to find a balance between oncologic efficacy and reducing adverse cardiovascular effects through timely publication and dissemination of peer-reviewed research. As an open access, online journal Cardiac-Oncology provides a high visibility platform for the publication of original research and expert reviews on the cardiovascular effects of cancer treatment. The discussions will be done in the following sections:

Session 5: Cardiac Care Equipment and Market:

With the never-ending advancements in technology, it is no doubt that we will find better ways to stay safe and remain healthy. Science is an evolving practice that changes as technology improves. This is especially beneficially in the health and safety field, where heart technology is concerned. The AED for example once did not exist. It was not until technology improved, and we realized that electrical shocks could be administered to the heart to save a life, that these lifesaving machines came into being! Heart technology has advanced to impressive and astonishing heights, and we can only expect it to continue to expand. For now, here are the newest Cardiac Technology Advancements.

The number of cardiac procedures performed increased steadily over the five years to 2017, providing overwhelming demand for operators in the Cardiologists industry. In particular, the growing burden of cardiovascular disease fostered increased demand. In addition, increasing rates of obesity and an aging baby-boomer population have resulted in an uptick in heart-related conditions. As a result, the early onset of chronic health conditions, such as heart disease, hypertension, and diabetes, bolstered demand for industry services. Improving economic conditions through 2022 are expected to underpin steady growth for cardiologists.

Session 6: Pediatric Cardiology:

Pediatric cardiology is concerned with diseases of the heart in the growing and developing the individual. As well as expertise in heart disease, pediatric cardiologists also need a thorough grounding in general pediatrics, in order to provide all-around patient care. Pediatric cardiologists broadly treat congenital heart disease (present at birth), arrhythmias (variations in heartbeat rhythm) and disturbances of circulatory function. The initial assessment performed by the pediatric cardiologist might start with a physical examination using a stethoscope, after which more detailed investigations may be suggested. Patients often present with complex diagnostic and medical problems and after the initial assessment, the pediatric cardiologist then chooses an optimal management plan. They work closely with a wide range of specialists as part of a multidisciplinary team to assess and treat patients. Pediatric cardiologists play a vital role in the teaching of medical students, doctors. GPs, nurses and paramedical staff. Most are also involved in research.

Session 7: Cardiovascular Risk Reduction:

Cardiovascular disease (CVD) is the leading cause of death and disability in the United States across all racial/ethnic groups. Much of the burden of CVD morbidity and mortality is associated with modifiable lifestyle risk factors. A disproportionate share of the burden of CVD and metabolic/vascular risk factors fall on racial and ethnic communities as a result of a constellation of social, environmental, biological, and systems factors. Disparities are most clearly evident for black compared with white Americans. Discussions will be there for other racial/ethnic minority populations indicate disparities for certain CVD risk factors or outcomes. This article provides a brief overview of the disparities in CVD health status, lifestyle risk factors, and health care. Successful CVD risk reduction strategies targeted to lifestyle behaviors are then described with a focus on research that demonstrates benefit in racial/ethnic minorities. General issues related to cultural competence and cultural tailoring are also discussed.

Session 8: Interventional Cardiology:

Interventional cardiology is a branch of cardiology that deals specifically with the catheter-based treatment of structural heart diseases. A large number of procedures can be performed on the heart by catheterization. This most commonly involves the insertion of a sheath into the femoral artery (but, in practice, any large peripheral artery or vein) and cannulating the heart under X-ray visualization (most commonly fluoroscopy). The radial artery may also be used for cannulation; this approach offers several advantages, including the accessibility of the artery in most patients, the easy control of bleeding even in anticoagulated patients, the enhancement of comfort because patients are capable of sitting up and walking immediately following the procedure, and the near absence of clinically significant sequelae in patients with a normal Allen test. Downsides to this approach include spasm of the artery and pain, inability to use larger catheters needed in some procedures, and more radiation exposure.

Session 9: Nuclear and Molecular Cardiology:

Molecular cardiology is a new and fast-growing area of cardiovascular medicine that aims to apply molecular biology techniques for the mechanistic investigation, diagnosis, prevention, and treatment of cardiovascular disease. As an emerging discipline, it has changed the conceptual thinking of cardiovascular development, disease etiology, and pathophysiology. Although molecular cardiology is still at a very early stage, it has opened a promising avenue for understanding and controlling the cardiovascular disease. With the rapid development and application of molecular biology techniques, scientists and clinicians are closer to curing heart diseases that were thought to be incurable 20 years ago. There clearly is a need for a more thorough understanding of the molecular mechanisms of cardiovascular diseases to promote the advancement of stem cell therapy and gene therapy for heart diseases.

Heart disease is the leading cause of death in the western world. Each year in the U.S.A, more than 500,000 men and women die from coronary artery disease. During the past two decades, major strides have been made in the diagnosis and treatment of heart disease. Nuclear Cardiology has played a pivotal role in establishing the diagnosis of heart disease and in the assessment of disease extent and the prediction of outcomes in the setting of coronary artery disease. Nuclear cardiology studies use noninvasive techniques to assess myocardial blood flow, evaluate the pumping function of the heart as well as visualize the size and location of a heart attack. Among the techniques of nuclear cardiology, myocardial perfusion imaging is the most widely used.

Session 10: Cardiovascular Toxicology and Pharmacology:

Cardiovascular Toxicology deals with the adverse effects on the heart or blood systems which result from exposure to toxic chemicals. It describes safety data of the detrimental effects of new cardiovascular drugs. Pharmacology of vascular endothelium deals with alterations of endothelial cells and the vasculature play a central role in the pathogenesis of a broad spectrum of the most dreadful of human diseases, as endothelial cells have the key function of participating in the maintenance of patent and functional capillaries.

Session 11: Cardiac Regeneration: Stem Cell Therapy:

Ischaemic heart disease is a leading cause of death worldwide. Injury to the heart is followed by loss of the damaged cardiomyocytes, which are replaced with fibrotic scar tissue. Depletion of cardiomyocytes results in decreased cardiac contraction, which leads to pathological cardiac dilatation, additional cardiomyocyte loss, and mechanical dysfunction, culminating in heart failure. This sequential reaction is defined as cardiac remodeling. Many therapies have focused on preventing the progressive process of cardiac remodeling to heart failure. However, after patients have developed end-stage heart failure, intervention is limited to heart transplantation. One of the main reasons for the dramatic injurious effect of cardiomyocyte loss is that the adult human heart has the minimal regenerative capacity. In the past 2 decades, several strategies to repair the injured heart and improve heart function have been pursued, including cellular and noncellular therapies. In this Review, we discuss current therapeutic approaches for cardiac repair and regeneration, describing outcomes, limitations, and future prospects of preclinical and clinical trials of heart regeneration. Substantial progress has been made towards understanding the cellular and molecular mechanisms regulating heart regeneration, offering the potential to control cardiac remodeling and redirect the adult heart to a regenerative state.
Stem Cell Therapy: Stem cell therapy as applied to cardiology has shown partial progress. A large number of patients with coronary artery disease experience angina with vessels that are not suitable for revascularization. Angina in so-called end-stage coronary artery disease is refractory to conventional medical therapy. Laboratory and preclinical studies have provided evidence for the safety and potential efficacy of autologous CD34+ stem cell therapies as treatment for angina. Clinical studies investigating intramyocardial transplantation of autologous CD34+ stem cells by catheter injection for patients with refractory angina show that this is safe and feasible. It remains unclear whether intracoronary infusion of CD34+ stem cells exerts beneficial effects in patients with angina as well. In a controlled clinical trial enrolling 112 patients with refractory angina, no myocardial infarction was observed during intracoronary infusion. No serious adverse events occurred in either group. The reduction in the frequency of angina episodes per week 3 and 6 months after infusion was significantly higher in the treatment group (-14.6 ± 4.8 at 3 months and -15.6 ± 4.0 at 6 months) than in the control group (-4.5 ± 0.3 and -3.0 ± 1.2, respectively; p < 0.01). Other efficacy parameters such as nitroglycerine usage, exercise time and the Canadian Cardiovascular Society class also showed an improvement in the treatment group compared to the control group.

Session 12: Myocardial Infarction:

Myocardial infarction (MI), commonly known as a heart attack occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle. The most common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw. Often it occurs in the center or left side of the chest and lasts for more than a few minutes. The discomfort may occasionally feel like heartburn. Other symptoms may include shortness of breath, nausea, feeling faint, a cold sweat, or feeling tired. About 30% of people have atypical symptoms. Women more often have atypical symptoms than men. Among those over 75 years old, about 5% have had an MI with little or no history of symptoms. An MI may cause heart failure, an irregular heartbeat, cardiogenic shock, or cardiac arrest. Most MIs occur due to coronary artery disease. Risk factors include high blood pressure, smoking, diabetes, lack of exercise, obesity, high blood cholesterol, poor diet, and excessive alcohol intake, among others. The complete blockage of a coronary artery caused by a rupture of an atherosclerotic plaque is usually the underlying mechanism of an MI. MIs are less commonly caused by coronary artery spasms, which may be due to cocaine, significant emotional stress, and extreme cold, among others.

Session 13: Geriatric Cardiology:

The emerging field of geriatric cardiology reflects a shift in clinical practice as the typical cardiovascular (CV) patient is now much older than in the past with distinctive goals and complexities related to age. Typical patients routinely present with coexisting geriatric syndromes that affect healthcare goals, care processes, and outcomes. Health systems and payers have also changed, with a greater focus on patient-centered outcomes like function and quality of life. Whereas CV medicine continues to progress with technical advances, it is no longer as certain if and how they will align with shifts in patients and payers. Within this context, several programs in geriatric cardiology have been developed over recent years, although the precise definition of what constitutes both clinical practice and training in this field is still evolving. Concomitantly, there has been a substantial increase in scholarship at the intersection of aging research and CV medicine: whereas even a decade ago the terms “geriatrics” and “Cardiology” were seldom mentioned together in the scientific literature, this has changed markedly. We expect that in the near future this nascent discipline will continue to grow to keep pace with the burgeoning older demographic and the evolving needs of an aging population. In this context, the purpose of this review is to highlight the development of geriatric cardiology, its current state, and future directions.

Session 14: Percutaneous Cardiovascular Interventions:

Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat narrowing (stenosis) of the coronary arteries of the heart found in coronary artery disease. After accessing the bloodstream through the femoral or radial artery, the procedure uses coronary catheterization to visualize the blood vessels on X-ray imaging. After this, an interventional cardiologist can perform a coronary angioplasty, using a balloon catheter in which a deflated balloon is advanced into the obstructed artery and inflated to relieve the narrowing; certain devices such as stents can be deployed to keep the blood vessel open. Various other procedures can also be performed. Primary PCI is the urgent use of PCI in people with acute myocardial infarction (heart attack), especially where there is evidence of heart damage on the electrocardiogram (ST elevation MI). PCI is also used in people after other forms of myocardial infarction or unstable angina where there is a high risk of further events. Finally, PCI may be used in people with stable angina pectoris, particularly if the symptoms are difficult to control with medication. PCI is an alternative to coronary artery bypass grafting (CABG, often referred to as "bypass surgery"), which bypasses stenotic arteries by grafting vessels from elsewhere in the body.

Session 15: Cardiac Medication: Drugs & Therapy

The article provides an overview of cardiovascular pharmacology by relating the mechanism of action of different classes of drugs to their effect on the control of the cardiovascular system. It will cover both newer types of drug and recent advances in the understanding of the older drugs. Understanding the mechanism of action of any new drug allows anesthetists to incorporate new drugs into their clinical practice. The cardiovascular system uses a complex series of control mechanisms to maintain homeostasis. The controls utilize multi-layered, interrelated mechanisms which help to minimize system redundancy and duplication. They utilize diverse methods from simple molecular function to principles of fluid dynamics in whole organs. This complexity has led to a diverse array of therapeutic agents being developed which target different areas. This diversity causes difficulty in constructing a system for classifying drugs which can also explain their mode of action.

Session 16: Cardiac Surgery and Transplantation:

Cardiac surgery, or cardiovascular surgery, is surgery performed on the heart or blood vessels by cardiac surgeons. It is often used to treat complications of ischemic heart diseases like coronary artery bypass grafting, to correct congenital heart disease; or to treat valvular heart disease from various causes, including endocarditis, rheumatic heart disease, and atherosclerosis. It also includes heart transplantation. There will be an expanded discussion regarding the new advanced technologies in cardiac transplantation and surgery processes.

  • CT Coronary Angiography (CTCA)
  • Coronary Artery Calcium Scoring
  • MRI Heart (Cardiac MRI)
  • Adult Oncology
  • Clinical Cardiology
  • Clinical Trials
  • Geriatric Oncology
  • Imaging
  • Nursing
  • Paediatric Oncology
  • Radiation Oncology
  • Translational Cardiology
  • Development of pacemaking
  • Cardiac conduction system lineages
  • New heart technology advancement
  • Role of platelets and antiplatelet therapy in cardiovascular disease
  • Molecular targets of antihypertensive drug therapy
  • Personalized medicine in cardiology
  • Real-world evidence and outcomes research

Annual Cardiologist Meeting welcomes presenters, exhibitors, and attendees from all over the world to Madrid, Spain. during November 26-27, 2018. The organizing committee of the event is preparing for an exciting and informative conference program including lectures, workshops, symposia on a wide variety of topics, poster presentations and various programs for participants from across the globe. We cordially invite you to join us at the Annual Cardiologist Meeting, where you will have a meaningful experience with scholars from overseas.  Organizing committee and all members of Cardiologist 2018 look forward to meeting you at Madrid, Spain.

Scope and importance:

The field of Cardiology is a specialization in medicine responsible for the diagnosis of disease, treatment and prevention measures of cardiovascular disease. Cardiologists study the dysfunctions of the heart, but the study of adult and child heart disorders are through dissimilar training pathways. Therefore, an adult cardiologist (often unqualified and called just cardiologist) is not fully trained to take care of children, and pediatric cardiologists are inadequately trained for adults. The surgical feature is not included in cardiology and are in the discipline of cardiothoracic surgery, For example, Cardiopulmonary bypass and Coronary artery bypass surgery are two surgical procedures performed by surgeons, not cardiologists.

Market Research:

The global market for interventional cardiology technologies reached an estimated $12.2 billion in 2014. According to a new study by Smithers Apex – The Future of Coronary Artery Disease Medical Devices to 2021 – it will grow to $22.5 billion (€20.9 billion) by 2021, with a year-on-year increase of 9.1%. Demand for coronary artery disease medical devices will grow through 2021 as clinically viable and cost-effective solutions are developed.

The global interventional cardiology market is anticipated to grow at a steady rate and will post a CAGR of more than 7% during the forecast period. The growing demand for minimally invasive (MI) procedures will drive the growth prospects for the global interventional cardiology market in the forthcoming years. Some of the major factors responsible for the growing preference for MI include faster recovery, less pain, fewer post-surgery infections, reduced hospital stays, minimized incision marks, controlled bleeding, and minimal complications and high accuracy. Also, MI artery stenting enhances the surgical precision by providing a 3D view of the patient and allowing the manipulation of small surgical tools for the placement of stents in the individual's body. As a result, 3D-MRI techniques for improved imaging have increased the popularity of MRI procedures, which will eventually increase the demand for cardiac surgeries.

Smithers Apex’s exclusive primary research and market data identifies three key trends that are driving the attractive evolution in the interventional cardiology technologies market.

Famous Renowned Medical Associations throughout the world:

  • American College of Cardiology, USA
  • Indian Heart Association, India
  • American Heart Association, USA
  • European Society of Cardiology, France
  • Heart Rhythm Society, USA
  • Canadian Cardiovascular Society, Canada
  • National Heart Foundation of Australia, Australia
  • Emirates Cardiac Society, UAE

Global University: Asia

  • National University of Singapore, Singapore
  • Tsinghua University, China
  • Peking University, China
  • University of Hong Kong, Hong Kong
  • Hong Kong University of Science and Technology, Hong Kong

Global University: Europe

  • Erasmus University Rotterdam, Netherlands
  • RWTH Aachen University, Germany
  • University of Groningen, Netherlands
  • The University of Edinburgh, Scotland
  • University of Copenhagen, Denmark

Global University: USA

  • Harvard University
  • University of Oxford
  • University of Cambridge
  • Johns Hopkins University
  • Stanford University

Global University: Middle East

  • Istanbul University, Turkey
  • King Saud University, Saudi Arabia
  • Cairo University, Egypt
  • Université de Tunis El Manar, Tunisia
  • American University of Beirut, Lebanon

Global Hospital: Middle East

  • Rambam Medical Center, Israel
  • Specialty Hospital, Jordan
  • Anadolu Medical Center, Turkey
  • Medicine Healthcare Group, Turkey
  • Istanbul Memorial Hospital, Turkey

Global Hospital: Asia

  • Mahkota Medical Centre, Malaysia
  • Bangkok Hospital Pattaya, Thailand
  • Fortis Escorts Heart Institute, India
  • Gleneagles Intan Medical Centre, Malaysia
  • Sunway Medical Centre, Malaysia

Global Hospital: Europe

  • Grupo Hospitalario Quirón, Spain
  • American Heart of Poland, Poland
  • SARAFIANOS Private Clinic, Greece
  • Hospital Ruber Internacional, Spain
  • Hygeia Hospital, Greece

Global Hospital: USA

  • Cleveland Clinic, Cleveland
  • New York-Presbyterian Hospital-Columbia and Cornell, New York
  • Mayo Clinic, Rochester
  • Cedars-Sinai Medical Center, Los Angeles
  • Massachusetts General Hospital, Boston

Global Funding Bodies: Asia

  • The Singapore Cardiac Society
  • National Heart Association of Malaysia

Global Funding Bodies: Europe

  • European Society of Cardiology
  • Association for European Paediatric Cardiology
  • Gulf Heart Association

Global Funding Bodies: Middle East

  • Emirates Cardiac Society
  • Israel Heart Society

Global Funding: USA

  • American Heart Association
  • American Society of Preventive Cardiology

Future Scope of Cardiology:

Global Interventional Cardiology market is estimated to reach US$22.2 billion by 2016. Global Interventional Cardiac Devices Industry market is worth US$20.6 billion by 2016, growing at a CAGR of 9.2% for the analysis period 2012-2018 respectively. North American region accounts for highest percentage approximately 35.8% (2015) of global share while Europe follows next with nearly 28.8% (2018) of the market. Asia-Pacific is the fastest growing region with a CAGR of 11.6% driving a market value of US$4.7 billion by 2015.

On a global scale, projections for Coronary Stents market share indicate nearly 47.1% by 2015 leaving the rest of the market to the Cardiac Catheters, PTCA/Coronary Guidewires, etc. By technology, Optical Coherence Tomography (OCT) is the fastest growing market. PCI Procedures market is expected to reach US$4.8 billion by 2016 across the world.

Conclusion:

Cardiac surgery is very important nowadays. Maximum people in the world suffer from cardiac disease and many people die with the cardiac disease just for poor treatment. So that's why it’s very important to improve in the treatment of cardiac disease and bring awareness among the people to get better treatment and get relief from cardiac disease. We have to explore the better ideas for the treatment of cardiac disease.

Learn More

Top searched Cardiology Related Terms:

Hypertension | Arrhythmias | Cardiac Disease Meeting | Cardiac Arrest Seminar | Cardiac Surgery Workshop | Cardiology Conference | Hypertension Conference | Electrocardiogram Workshop | Cardio Oncology Conference | Coronary Artery Disease Conference | Pediatric Cardiology Event | Pediatric Cardiology | Cardiovascular Pharmacology | Cardiac Nursing | Clinical Cardiology | Cardio-Oncology | Cardiovascular Surgeries | Cardiac Regeneration | Case Reports on Cardiology | Interventional Cardiology | Nuclear Cardiology | Obesity & Diabetes | Vascular Heart Disease | Cardiomyopathy & Heart Failure | Cardiovascular Diseases during Pregnancy | Cardiac Diagnostic Test | Cardiovascular Radiology and Intervention | Heart Stroke | Advanced Cradiac Nursing Practice | Pediatric Cardiology | Cardiac Tamponade | Cardiac Surgery | Cardio Oncology | Cardiotonic | Cardiomyoplasty | Congenital Heart Disease | Arrhythmias | Electrocardiography | Cardiac Catheterization | Cardiac Glycosides

  • Preventive Cardiology and Lifestyle Medicine
  • Echo Cardiography and Cardiac Imaging
  • Cardiac-Oncology
  • Cardiac Care Equipment and Market
  • Paediatric Cardiology
  • Cardiovascular Risk Reduction
  • Interventional Cardiology
  • Nuclear and Molecular Cardiology
  • Cardiovascular Toxicology and Pharmacology
  • Cardiac Regeneration: Stem Cell Therapy
  • Myocardial Infarction
  • Percutaneous Cardiovascular Interventions

9 Organizing Committee Members

OCM Member
Heinz-Peter Schultheiss

CEO
Institute for Cardiac Diagnostic and Therapy
Germany

OCM Member
Ganesh Kumar Mani

Chairman
MAX Smart Super Specialty Hospital
India

OCM Member
Baris Cankaya

Professor
Marmara University Hospital
Turkey

OCM Member
Marie Vazquez Morgan

Associate Professor
Louisiana State University
USA

OCM Member
Mohamed Mahmoud Elseweidy

Professor
Zagazig University
Egypt

OCM Member
Yasmine S. Ali

Chief Editor (WebMD)
Preventive Cardiologist & Clinical Lipidologist
USA

OCM Member
Najeebullah Jalazi

MD, Interventional Cardiologist
Kabul Medical University
Afganistan

OCM Member
Leo Antonovich Bokeriya

Director & Chief Cardiac Surgeon
Ministry of Health of Russia
Russia

OCM Member
Anna Norhammar

Associate Professor
Karolinska Institute
Sweden

More...

Media Partners & Collaborations

Media Partner

Media Partner

Media Partner

Media Partner

Media Partner

Media Partner

Media Partner

Media Partner

Media Partner

Media Partner

Media Partner

Media Partner

Media Partner

Media Partner

Media Partner